Single dose phakmacokinetics of gestodene in women after intravenous and oral administration

References

1. • Orme M.L.E.
   • Back D.J.
   • Breckenridge A.M.
   Clinical pharmacokinetics of oral contraceptive steroids.
   Clinical Pharmacokinetics. 1983; 8: 95-136
   • Google Scholar
2. • Elger W.
   • Steinbeck H.
   • Schillinger E.
   • Losert W.
   • Beier S.
   Endocrine-pharmacological profile of gestodene.
   in: Elstein M. Gestodene. Parthenon Publish, 1987: 19-33
   • Google Scholar
3. • Nieuweboer B.
   • Tack J.
   • Hümpel M.
   • Täuber U.
   Development and application of a radioimmunoassay of the new progestogen gestodene.
   Contraception. 1989; 40: 313-323
   • Google Scholar
4. • Poland H.
   • Woloszczak R.
   A program library for computing the parameters of linear compartment models in pharmacokinetics.
   Int. J. Bio. Med. Comp. 1980; 11: 115-128
   • Google Scholar
5. • Hümpel M.
   • Wendt H.
   • Pommerenke G.
   • Weiss C.
   • Speck U.
   Investigations of pharmacokinetics of levonorgestrel to specific consideration of a possible first-pass effect in women.
   Contraception. 1978; 17: 207-220
   • Google Scholar
6. • Back D.J.
   • Breckenridge A.M.
   • Crawford F.E.
   • McIver M.
   • Orme M.L.E.
   • Park B.K.
   • Rowe P.H.
   • Smith E.
   Kinetics of norethindrone in women II. Single-dose kinetics.
   Clin. Pharmacol. Therap. 1978; 24: 448-453
   • Google Scholar
7. • Back D.J.
   • Bates M.
   • Breckenridge A.M.
   • Hall J.M.
   • McIver M.
   • Orme M.L.E.
   • Park B.K.
   • Rowe P.H.
   The pharmacokinetics of levonorgestrel and ethinylestradiol in women-studies with Ovran and Ovranette.
   Contraception. 1981; 23: 229-239
   • Google Scholar
8. • Back D.J.
   • Breckenridge A.M.
   • Crawford F.E.
   • McIver M.
   • Orme M.L.E.
   • Rowe P.H.
   • Smith E.
   Kinetics of norethindrone in women I. Radio-immunoassay and concentrations during multiple dosing.
   Clin. Pharmacol. Therap. 1978; 24: 439-447
   • Google Scholar
9. • Back D.J.
   • Grimmer S.F.M.
   • Rogers S.
   • Stevenson P.J.
   • Orme M.L.E.
   Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration.
   Contraception. 1987; 36: 471-479
   • Google Scholar
10. • Back D.J.
    • Grimmer S.F.M.
    • Shenoy N.
    • Orme M.L.E.
    Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel.
    Contraception. 1987; 35: 619-626
    • Google Scholar
11. • Viinikka L.
    • Ylikorkala O.
    • Vihko R.
    • Wijnand J.P.
    • Booij M.
    • van der Veen F.
    Metabolism of a new synthetic progestagene, Org 2969, in female volunteers Pharmacokinetics after an oral dose.
    Europ. J. Clin. Pharmacol. 1979; 15: 349-355
    • Google Scholar
12. • Kuhl J.
    • Jung-Hoffmann C.
    • Heidt F.
    Serum levels of 3-ketodesogestrel and SHBG during 12 cycles of treatment with 30 μg ethinyl estradiol and 150 μg desogestrel.
    Contraception. 1988; 38: 381-390
    • Google Scholar
13. • Kuhl H.
    • Jung-Hoffmann C.
    • Heidt F.
    Alterations in the serum levels of gestodene and SHBG during 12 cycles of treatment with 30 μg ethinylestradiol and 75 μg gestodene.
    Contraception. 1988; 38: 477-486
    • Google Scholar
14. • Lepot M.R.
    • Gaspard U.J.
    Metabolic effects of two low-dose triphasic oral contraceptives containing ethinylestradiol and levonorgestrel or gestodene.
    Int. J. Fertil. 1987; 32 (Suppl.): 15-20
    • Google Scholar
15. • Hammond G.L.
    • Langley M.S.
    • Robinson P.
    • Nummi S.
    • Lund L.
    Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel.
    Fertility and Sterlity. 1984; 42: 44-51
    • Google Scholar
16. • Kuhl H.
    • Jung-Hoffmann C.
    Divergent effects of two low-dose oral contraceptives on sex hormone binding and free testosterone.
    Amer. J. Obst. Gynecol. 1987; 156: 199-203
    • Google Scholar
17. • Palatsi R.
    • Hirvensalo E.
    • Liukko P.
    • Malmiharju T.
    • Mattila L.
    • Riihiluoma P.
    • Ylostalo P.
    Serum total and unbound testosterone and sex hormone binding globulin (SHBG) in female acne patients treated with two different oral contraceptives.
    Acta Derm. Venerol. (Stockh.). 1984; 64: 517-523
    • Google Scholar
18. • Hammond G.K.
    • Lähteenmäki P.L.A.
    • Lähteenmäki P.
    • Luukkainen T.
    Distribution and percentages of non-protein bound contraceptive steroids in human serum.
    J. Steroid Biochem. 1982; 17: 375-380
    • Google Scholar

19. Follow K., Heubner A., Grill H.-J., Elger W., Henderson D., Beier S., Manz B. Gestodene: A novel synthetic progestin. Characterization of binding to receptor proteins. (in press)

    • Google Scholar
20. • Jenkins N.
    • Fotherby K.
    Binding of the contraceptive steroids norgestrel and norethisterone in human plasma.
    J. Steroid Biochem. 1980; 13: 512-527
    • Google Scholar
21. • Täuber U.
    • Hasselblatt G.
    • Matthes H.
    Effect of a defined break of intake of Triquilar on serum levels of levonorgestrel and of endogenous sex hormones.
    in: XII World Congress of Gynecology and Obstetrics, Rio de Janeiro1988 (Volume of Abstracts)
    • Google Scholar
22. • Liukko P.
    • Erkkola R.
    • Bergink E.W.E.
    Progestagen-dependent effect on some plasma proteins during oral contraception.
    Gynecol. Obstet. Invest. 1988; 25: 118-122
    • Google Scholar

23. Hümpel M., Li Qi-gui. Serum protein binding characteristics of cyproterone acetate, gestodene, levonorgestrel and norethisterone in rat, rabbit, dog, monkey and man. (submitted for publication)

    • Google Scholar

24. Kuhnz W., Pfeffer M., Al-Yacoub G. Protein binding of the contraceptive steroids gestodene, 3-ketodesogestrel and ethinylestradiol. J. Steroid Biochem. (submitted for publication)

    • Google Scholar